痰热清注射液对阻塞性睡眠呼吸暂停低通气综合征患者血浆TXB_2、6-Keto-PGF_(1α)和ACA的影响

The Effect of Tanreqing Injection(痰热清注射液) on the Levels of TXB_2,6-Keto-PGF_(1α) and ACA in Plasma of Patients with Obstrutive Sleep Apnea-Hypopnea Syndrome

目的探讨痰热清注射液对阻塞睡眠呼吸暂停低通气综合征(OSAHS)患者血浆血栓素B2(TXB2)、6-酮-前列腺素Flα(6-Keto-PGF1α)和血清抗心磷脂抗体(ACA)的影响。方法选择经多导睡眠图(PSG)确诊的OSAHS患者120例为试验组,根据睡眠呼吸暂停低通气指数(AHI)、最低血氧饱和度(SaO2min)将OS-AHS患者分为轻、中/重度组,并设正常对照组30例;78例中/重度OSAHS患者为治疗组,应用痰热清注射液治疗;用酶联免疫吸附试验(ELISA)检测各组TXB2、6-Keto-PGF1α和ACA,比较OSAHS组与对照组、治疗组治疗前后各项指标的差异。结果治疗组血浆TXB2、血清ACA-IgG及ACA-IgM均明显高于对照组,经痰热清注射液治疗后上述指标明显下降;治疗组血浆6-Keto-PGF1α明显低于对照组;相关性分析表明,TXB2、ACA与AHI呈正相关,与SaO2呈负相关;而6-Keto-PGF1α与AHI呈负相关,与SaO2呈正相关。结论OSAHS患者存在血管内皮细胞功能障碍,TXB2、6-Keto-PGF1α和ACA在OSAHS患者血栓栓塞性疾病高发病率中起重要作用,并与夜间低氧血症密切相关;提示OSAHS患者易患血栓栓塞性疾病,痰热清注射液可有效逆转上述改变。

Objective:To observe the changes of TXB2, 6-Keto-PGF1α and anticardiolipin antibody(ACA) in patients with obstructive sleep apnea-hypopnea syndrome(OSAHS) treated by Tanreqing Injection(痰 热 清 注 射 液 ). Methods:120 Patients with OSAHS confirmed by polysomnography (PSG) were selected as the trial group,all cases were divided into light and moderate/severe group according to AHI and SaO2min,and 30 normal persons without OSAHS were recruited as the control group.78 patients with severe OSAHS were treated by Tanreqing Injection. Plasma levels of TXB2, 6-Keto-PGF1α and anticardiolipin antibody were detected by enzyme-linked immunosorbent assay(ELISA). Compared the difference of these index between trial group and control group before and after treatment. Results:Plasma(serum) level of TXB2(ACA) was significantly higher in patients with moderate to severe OSAHS than that in the control group,and Tanreqing Injection therapy decreased the level significantly. Plasma level of 6-Keto-PGF1α was significantly lower than that in the control group. TXB2 and ACA were correlated positively with AHI,and negatively with minimal oxygen saturation. 6-Keto-PGF1α was correlated negatively with AHI,and positively with minimal oxygen saturation.Conclusions:The results indicate that patients with OSAHS have vascular endothelium function obstacle.TXB2, 6-Keto-PGF1α , ACA may be associated with the high prevalence of thromboembolism in patients with OSAHS,and were correlated positively with low oxygen saturation in night.The results indicate that patients with OSAHS are susceptible to thromboembolism disease Tanreqing Injection therapy is effective in correcting TXB2,6-Keto-PGF1α ,ACA.